X

Drug Profile

CBE 401

Alternative Names: CBE-401

Latest Information Update: 26 Feb 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cell BioEngines
Class Cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Thrombocytopenia

Most Recent Events

11 Jan 2024 CBE 401 is available for licensing as of 11 Jan 2024. https://cellbioengines.com/our-pipeline
11 Jan 2024 BioEngines plans to file IND application for CBE 401 in Q3 of 2025 (Cell BioEngines pipeline, January 2024)
10 Jan 2024 Preclinical trials in Thrombocytopenia in USA (Parenteral) (Cell BioEngines pipeline, January 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com